Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vericiguat in Vasospastic Angina
NL-OMON60225Phase 2Completed
- Sponsor
- Amsterdam University Medical Center
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vericiguat in Coronary vasospasm (CAS), sponsored by Amsterdam University Medical Center. Primary endpoints: Area under the curve for cutaneous microvascular conductance during acetylcholine iontophoresis and Daily angina episodes. Started Feb 2025; status: completed.
02
Drugs
vericiguat
03
Conditions
Coronary vasospasm (CAS)
Beyond the preview
Go deeper on NL-OMON60225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60225.